

## Errata

Volume 4, page 187: Correspondence e-mail should read:

Andre.Korrat@oncotest.de

Volume 4, page 194: Table IV should be replaced with:

Table IV. *B. Cyclophosphamide efficacy in clinically resistant or untested tumor types: results for 37 tested tumors and predictions for 75 untested tumors.*

| Cancer type          | CY real |    |       |     | CY predicted |    |       |     | Cy real + predicted |    |       |     |
|----------------------|---------|----|-------|-----|--------------|----|-------|-----|---------------------|----|-------|-----|
|                      | R       | NR | Total | %   | R            | NR | Total | %   | R                   | NR | Total | %   |
| CNS                  |         | 1  | 1     | 0%  |              |    |       |     |                     |    |       |     |
| Colon                | 1       | 7  | 8     | 13% | 3            | 16 | 19    | 16% | 4                   | 23 | 27    | 15% |
| Gastric              |         | 2  | 2     | 0%  |              | 6  | 6     | 0%  |                     | 8  | 8     | 0%  |
| Head and Neck        |         | 1  | 1     | 0%  | 1            | 3  | 4     | 25% | 1                   | 4  | 5     | 20% |
| Liver                |         |    |       |     |              | 2  | 2     | 0%  |                     | 2  | 2     | 0%  |
| Lung NSCLC           | 3       | 7  | 10    | 30% | 4            | 24 | 28    | 14% | 7                   | 31 | 38    | 18% |
| Pancreas             |         | 2  | 2     | 0%  |              | 3  | 3     | 0%  |                     | 5  | 5     | 0%  |
| Pleural mesothelioma |         | 3  | 3     | 0%  | 1            | 1  | 2     | 50% |                     | 4  | 5     | 0%  |
| Prostate             |         | 2  | 2     | 0%  |              |    |       |     |                     |    |       |     |
| Renal                | 1       | 6  | 7     | 14% |              | 9  | 9     | 0%  |                     | 15 | 16    | 0%  |
| Uterus cervix        | 1       |    |       |     |              | 2  | 2     | 0%  |                     | 2  | 2     | 0%  |
| Total                | 6       | 31 | 37    | 16% | 9            | 66 | 75    | 12% | 15                  | 97 | 112   | 13% |

Volume 4, page 195, line 8: The sentence should read:

The products of at least 18 of these genes interact with DNA and the products of 12 of these genes are already known to interact at least indirectly with CY.

Volume 4, page 202: Table V should be replaced with:

| Tumor     | T/C[%] | real | predicted |
|-----------|--------|------|-----------|
| CXF_280   | 1      | R    | R         |
| GXF_281   | 1      | R    | R         |
| GXF_97    | 1      | R    | R         |
| LXFL_529  | 1      | R    | R         |
| LXFS_605  | 1      | R    | R         |
| MAXF_401  | 1      | R    | R         |
| MAXF_449  | 2      | R    | R         |
| LXFA_289  | 3      | R    | R         |
| LXFE_211  | 3      | R    | R         |
| MAXF_MX1  | 5      | R    | R         |
| LXFE_409  | 6      | R    | R         |
| OVXF_1023 | 8      | R    | R         |
| CXF_260   | 9      | R    | R         |
| MAXF_583  | 11     | R    | R         |
| MAXF_508  | 13     | R    | R         |
| LXFA_629  | 16     | R    | R         |
| GXF_251   | 17     | R    | R         |
| LXFA_400  | 18     | R    | R         |
| MAXF_1384 | 18     | R    | R         |
| GXF_602   | 24     | R    | R         |
| CXF_1103  | 45     | NR   | R         |
| LXFE_397  | 56     | NR   | R         |
| MAXF_1162 | 58     | NR   | R         |
| MAXF_857  | 69     | NR   | R         |
| MAXF_MCF7 | 73     | NR   | R         |
| OVXF_899  | 76     | NR   | R         |

  

| Tumor     | T/C[%] | real | predicted |
|-----------|--------|------|-----------|
| PXF_541   | 32     | NR   | NR        |
| CXF_264   | 34     | NR   | NR        |
| PAXF_546  | 34     | NR   | NR        |
| CXF_269   | 35     | NR   | NR        |
| CXF_676   | 39     | NR   | NR        |
| MAXF_574  | 39     | NR   | NR        |
| RXF_944LX | 42     | NR   | NR        |
| CXF_975   | 44     | NR   | NR        |
| MEXF_274  | 45     | NR   | NR        |
| OVXF_1353 | 48     | NR   | NR        |
| LEXF_1189 | 52     | NR   | NR        |
| MEXF_1341 | 53     | NR   | NR        |
| CNXF_498  | 54     | NR   | NR        |
| MEXF_276  | 54     | NR   | NR        |
| MEXF_1732 | 55     | NR   | NR        |
| CXF_158   | 56     | NR   | NR        |
| CXF_609   | 57     | NR   | NR        |
| LXFL_1072 | 59     | NR   | NR        |
| CXF_647   | 64     | NR   | NR        |
| RXF_423   | 64     | NR   | NR        |
| LXFA_526  | 67     | NR   | NR        |
| MEXF_514  | 67     | NR   | NR        |
| RXF_631   | 68     | NR   | NR        |
| CXF_1729  | 69     | NR   | NR        |
| PAXF_736  | 70     | NR   | NR        |
| RXF_1393  | 72     | NR   | NR        |
| CXF_886   | 74     | NR   | NR        |
| CXF_243   | 79     | NR   | NR        |
| MEXF_535  | 79     | NR   | NR        |
| RXF_486   | 80     | NR   | NR        |
| BXF_T24   | 81     | NR   | NR        |
| RXF_1220  | 81     | NR   | NR        |
| RXF_393   | 89     | NR   | NR        |
| SXF_1410  | 89     | NR   | NR        |
| GXF_209   | 2      | R    | NR        |
| MEXF_989  | 10     | R    | NR        |
| PAXF_1657 | 27     | R    | NR        |

  

| <i>In vivo study</i>                            |  |
|---|--|
| <b>63 Tumors tested</b>                         |  |
| <b>23 (37%) Responsive(R) T/C&lt;30%</b>        |  |
| <b>40 (63%) Not responsive (NR) T/C&gt;=30%</b> |  |

  

| Predicted | <i>in vivo real</i>      |
|-----------|--------------------------|
| R 26      | R 20 (77%)<br>NR 6 (23%) |

  

| Predicted | <i>in vivo real</i>     |
|-----------|-------------------------|
| NR 37     | R 3 (8%)<br>NR 34 (92%) |

Volume 4, page 203: Table VI should be replaced with:

| Tumor       | T/C[%] | real | pred |
|-------------|--------|------|------|
| LXFL_529    | 2      | R    | R    |
| LXFS_573    | 3      | R    | R    |
| LXFS_650    | 3      | R    | R    |
| MEXF_276    | 4      | R    | R    |
| LXFE_409    | 5      | R    | R    |
| RXF_393     | 8      | R    | R    |
| LXFS_605    | 9      | R    | R    |
| SXF_627     | 22     | R    | R    |
| PXF_537     | 23     | R    | R    |
| LEXF_1189   | 24     | R    | R    |
| LXFE_937    | 25     | R    | R    |
| MEXF_989    | 25     | R    | R    |
| LXFL_1072   | 29     | R    | R    |
| RXF_944LX   | 29     | R    | R    |
| GXF_281     | 32     | R    | R    |
| BXF_1218    | 33     | R    | R    |
| MAXF_MX1    | 33     | R    | R    |
| CXF_280     | 34     | R    | R    |
| GXF_97      | 34     | R    | R    |
| MAXF_574    | 42     | NR   | R    |
| SXF_1410    | 49     | NR   | R    |
| LXFE_397    | 52     | NR   | R    |
| MEXF_514    | 55     | NR   | R    |
| LXFS_615    | 62     | NR   | R    |
| PXF_541     | 64     | NR   | R    |
| MEXF_535    | 81     | NR   | R    |
| LEXF_CCRFCM | 86     | NR   | R    |
| LXFA_289    | 95     | NR   | R    |

| Tumor      | T/C[%] | real | pred |
|------------|--------|------|------|
| BXF_1228   | 35     | NR   | NR   |
| BXF_T24    | 35     | NR   | NR   |
| RXF_1393   | 35     | NR   | NR   |
| OVXF_1353  | 36     | NR   | NR   |
| CXF_1788   | 37     | NR   | NR   |
| RXF_486    | 37     | NR   | NR   |
| GXF_602    | 39     | NR   | NR   |
| MAXF_401   | 39     | NR   | NR   |
| LXFL_430   | 41     | NR   | NR   |
| LXFA_629   | 42     | NR   | NR   |
| OVXF_899   | 43     | NR   | NR   |
| PAXF_1657  | 47     | NR   | NR   |
| OVXF_SKOV3 | 50     | NR   | NR   |
| PAXF_546   | 53     | NR   | NR   |
| RXF_631    | 54     | NR   | NR   |
| RXF_1220   | 56     | NR   | NR   |
| LXFE_211   | 57     | NR   | NR   |
| MAXF_1322  | 57     | NR   | NR   |
| MAXF_1384  | 58     | NR   | NR   |
| MAXF_857   | 59     | NR   | NR   |
| CXF_158    | 60     | NR   | NR   |
| CXF_975    | 62     | NR   | NR   |
| CXF_1103   | 66     | NR   | NR   |
| GXF_251    | 67     | NR   | NR   |
| MAXF_583   | 67     | NR   | NR   |
| MAXF_MCF7  | 71     | NR   | NR   |
| MEXF_274   | 72     | NR   | NR   |
| LXFA_677   | 75     | NR   | NR   |
| LXFS_538   | 75     | NR   | NR   |
| CXF_609    | 80     | NR   | NR   |
| MAXF_1162  | 82     | NR   | NR   |
| CXF_243    | 84     | NR   | NR   |
| BXF_1258   | 96     | NR   | NR   |
| RXF_423    | 98     | NR   | NR   |
| GXF_209    | 5      | R    | NR   |
| PAXF_736   | 10     | R    | NR   |
| MAXF_449   | 12     | R    | NR   |
| LXFA_526   | 15     | R    | NR   |

***In vivo study***

**66 Tumors tested**

**23 (35%) Responsive(R) T/C<35%**

**43 (65%) Not responsive (NR) T/C>=35%**

| Predicted | <i>in vivo real</i>      |
|-----------|--------------------------|
| R 28      | R 19 (68%)<br>NR 9 (32%) |

| Predicted | <i>in vivo real</i>      |
|-----------|--------------------------|
| NR 38     | R 4 (11%)<br>NR 34 (89%) |